ライフサイエンスコーパス: intralipid

1 ure to isoflurane, control, propofol, or 10% intralipid.

2 ng single exponential decay kinetics in a 2% intralipid solution.

3 while imaging the CAs before and after a 20% intralipid infusion to induce hypertriglyceridemia.

4 en 0 and 120 minutes, high-fat nutrient (20% intralipid) was infused via a postpyloric catheter into

5 sion of normal saline and 2) infusion of 20% intralipid (IL).

6 NS + FAT; n = 6) received an infusion of 20% intralipid + heparin (0.5 U x kg(-1) x min(-1)) to clamp

7 Two-hour intakes of 5% intralipid were measured (5-120 min) in seven inbred (BA

8 0) of the doses tested, but failed to affect intralipid intake in BALB/c mice.

9 the doses tested, and also failed to affect intralipid intake in BALB/cJ mice.

10 ation of the fluorophore rhodamine 800 in an intralipid suspension and in chicken tissue.

11 els were raised approximately twofold via an intralipid/heparin infusion in eight lean women.

12 Fat-free milk and intralipid, a source of vegetable triglycerides, were wi

13 Both intralipid infusion and a low-carbohydrate diet resulted

14 rate and leg glucose uptake was decreased by intralipid.

15 Plasma FFAs were increased by intralipid/heparin infusion (3 h), insulin was increased

16 free fatty acid (FFA) levels by twofold (by intralipid infusion during 11 mmol/l glucose clamp) resu

17 signaling mechanisms differentially control intralipid intake across different mouse strains, sugges

18 or combined with phenylephrine, dobutamine, intralipid infusion, or intralipid infusion and dobutami

19 In vivo in dogs, intralipid administration significantly increased the in

20 Three dogs were studied during intralipid infusion alone under resting conditions.

21 antagonism to alter intake of fat emulsions (intralipid) in mice.

22 for and intake of solid and emulsified fat (intralipid) solutions vary across different mouse strain

23 Eighteen patients underwent 8-hour intralipid/heparin-infusion (high FFA) and hyperinsuline

24 used to measure the concentration of RhB in intralipid and to measure pH using 6-carboxyfluorescein.

25 lities of SCH23390 and naltrexone to inhibit intralipid intake across strains.

26 -fold and 9.3-fold more potent in inhibiting intralipid intake in the most sensitive (DBA/2) relative

27 stigated sites compared with the rested leg, intralipid impaired TBC1D4 S341 phosphorylation compared

28 +/- 0.25 mmol/l; P = 0.009), despite matched intralipid infusion rates.

29 Using a combination of intralipid and/or nicotinic acid infusions and a pancrea

30 a clamp with either infusion of glycerol or intralipid.

31 ephrine, dobutamine, intralipid infusion, or intralipid infusion and dobutamine.

32 rimental trials, differing only by saline or intralipid infusion.

33 or exercise was followed by 7 h of saline or intralipid infusion.

34 The present simulations reveal O-H:::O-P intralipid hydrogen bonding occurs 99% of the time, and

35 dose-dependently and differentially reduced intralipid intake at all five (DBA/2, SWR, CD-1), four (

36 dose-dependently and differentially reduced intralipid intake at all four (DBA/2), three (SWR, SJL),

37 s decreased in both acute insulin-resistant (intralipid infusion) and chronic insulin-resistant state

38 arized emission of Rh800 from the scattering intralipid or tissue.

39 , SGU was significantly decreased during the intralipid/heparin versus saline infusion (30 +/- 2 vs.

40 is accompanied by significant changes in the intralipid interactions within the bilayer.

41 icantly higher during the OGL clamp with the intralipid/heparin infusion than with the saline infusio

42 eated animals (TZD + FFA2) were infused with intralipid at a higher infusion rate (44%) to match the

43 efore and after elevation of FFA levels with intralipid infusion (by +535%, n=9) and a 5-day high-fat

44 159 and 787 +/- 187 ml/min with and without intralipid infusion, respectively).

45 A levels decreased during the clamps without intralipid but increased above basal during the clamps w